Bart van Rhijn

Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY.

International Distillers & Vintners Ltd. is a British company that imports and distributes specialty beers and spirits worldwide, including the Americas. The joint venture company's mission is to provide nationwide service to their customers while committing to long term brand building activities. The company prides itself on its broad range of high-quality products, including wines, spirits, and beer from countries around the world. The company is the exclusive importer and distributor of a variety of products.

MSD Vaccines Ltd. manufactures and supplies vaccines. Its main way of achieving this goal is to develop and make available innovative vaccines against a wide spectrum of diseases. It also dedicated to increasing the understanding of the value of vaccines and vaccination by providing relevant and accurate information on their quality, safety and efficacy. The company was founded in 1975 and is headquartered in Maidenhead, the United Kingdom.

Institut Mines-Télécom provides information technology education services. It is an organization for higher education and research in the information and communication technologies and sciences. The firm also provides information technology education services. The company was founded in 1844 and is headquartered in Paris, France.

Sanofi Pasteur MSD SNC is engaged in the wholesale of pharmaceutical products. The company was founded on August 16, 1993 and is headquartered in Lyon, France.

Capgemini Consulting SAS provides management consulting and outsourcing services. The firm advises and supports organizations in transforming their business. The company was founded on July 12, 2004 and is headquartered in Paris, France.

AXA Partners Holdings Ltd. provides accident, sickness, and unemployment insurance services. The company was founded on September 29, 2003 and is headquartered in London, the United Kingdom.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

Part of Takeda Pharmaceutical Co., Ltd., Shire Pharmaceuticals LLC is an American company that manufactures pharmaceutical products.

Part of Merck & Co., Inc., Sanofi Pasteur MSD Ltd. is a company based in Dublin, Ireland. The Irish company develops and produces vaccines.

Part of Merck & Co., Inc., Sanofi Pasteur MSD SA is a company based in Madrid, Spain. The Spanish company develops vaccines.

Roc SA provides housing development services.

Medisix Therapeutics, Inc. develops novel cellular therapies to address T cell malignancies. The company is headquartered in Singapore.

Part of PharmaEngine, Inc., Pharmaengine Europe SARL develops pharmaceutical products for cancer diseases. The company is based in Paris, France. The CEO of the French company is Alain Herrera.

Part of Sia Partners SASU, Latham BioPharm Group, Inc. is a leading life science consulting company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies to solve complex business, regulatory, and product development challenges. The company was founded in 1996 by Peter Latham and is based in Elkridge, MD. LBG's core services include comprehensive functional expertise in vaccines, therapeutics, cell & gene therapy, medical devices, and diagnostics. The company provides technical expertise, quality oversight, strategic analysis, and knowledge management necessary to successfully navigate the complex roadmap of life sciences product development. LBG has helped clients identify, evaluate, fund, manage, and monetize opportunities, generating over $1 billion in non-dilutive funding and over $100 million in licensing fees and investments. Latham BioPharm Group was acquired by Sia Partners SASU on October 14, 2022.

M2care SAS is a French healthcare company founded in 2017. The company is based in Lyon, France. M2care is a team of passionate entrepreneurs who invest in human and financial value to co-found, co-operate, and co-develop innovative projects in the healthcare sector until they reach the patient.

Gustave Roussy Transfert is a subsidiary of Gustave Roussy, the first cancer control center in France, which places innovation at the heart of care and research against cancer. The private company is based in Villejuif, France. The French company's main mission is to identify, protect, promote, and support the scientific, technological, and medical resources of Gustave Roussy. Gustave Roussy Transfert has designed a program called "Better Living Cancer" to support cancer patients during and after treatments through complementary approaches and practices to improve their quality of life. The program includes physical activity sessions, mindfulness meditation courses, and aesthetic care.

EMERCell SAS is an oncology company based in Montpellier, France. The French company is focused on developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's lead drug candidate, NK-001, is intended for the treatment of lymphoma patients who are refractory to conventional therapies. EMERCell collaborates with numerous industrial and academic partners and has received support from the Occitanie region (ADI) and Bpifrance. The company was founded in 2013 by Patrick Henno and Martin Villalba and is a member of Eurobiomed.

Onward Therapeutics SA is a Swiss development stage oncology company that focuses on identifying innovative technologies and developing breakthrough medicines for cancer treatment. The private company was founded by Alain Herrera and is based in Biopole, Switzerland, a life sciences campus in Epalinges, near Lausanne. The company acquires licenses for potential development candidates and invests in partners with transformative technology platforms. Onward recently licensed a preclinical stage bispecific antibody targeting two immune checkpoints and invested in the series A financing round in Biomunex Pharmaceuticals SAS. Onward also has an affiliate in Montpellier, France, and an office in Boston.